SAB Biotherapeutics
SABS

$2.74

7.03%

Market Cap: $25.3M

About: SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Employees: 57

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

2.32% less ownership

Funds ownership: 36.2% [Q1] → 33.88% (-2.32%) [Q2]

8% less funds holding

Funds holding: 24 [Q1] → 22 (-2) [Q2]

36% less capital invested

Capital invested by funds: $15.2M [Q1] → $9.69M (-$5.47M) [Q2]

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$6

119%

upside

Avg. target

$16

484%

upside

High target

$25

812%

upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

Oppenheimer Leland Gershell 62% 1-year accuracy 31 / 50 met price target	338%upside $12	Outperform Reiterated	12 Sept 2024
Chardan Capital Keay Nakae 38% 1-year accuracy 21 / 56 met price target	812%upside $25	Buy Maintained	9 Sept 2024
Oppenheimer Leland Gershell 62% 1-year accuracy 31 / 50 met price target	338%upside $12	Outperform Initiated	28 Aug 2024
Chardan Capital Keay Nakae 38% 1-year accuracy 21 / 56 met price target	812%upside $25	Buy Maintained	12 Aug 2024
HC Wainwright & Co. Edward White 27% 1-year accuracy 33 / 121 met price target	119%upside $6	Buy Reiterated	12 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 13 articles about SABS published over the past 30 days

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into SAB Biotherapeutics, Inc.

NEW YORK, NY / ACCESSWIRE / September 19, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into SAB Biotherapeutics, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into SAB Biotherap

NEW YORK, NY / ACCESSWIRE / September 18, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into SAB Biotherap

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into SAB Biotherap

NEW YORK, NY / ACCESSWIRE / September 16, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into SAB Biotherap

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into SAB Biotherap

NEW YORK, NY / ACCESSWIRE / September 17, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into SAB Biotherap

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into SAB Biotherapeutics, Inc.

NEW YORK, NY / ACCESSWIRE / September 13, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into SAB Biotherapeutics, Inc.

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference

MIAMI, Sept. 13, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of T1D, today announced that Chairman and CEO Samuel J. Reich will be participating in a fireside chat at the 2024 Cantor Global Healthcare Conference, September 17-19th, 2024.

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into SAB Biotherap

NEW YORK, NY / ACCESSWIRE / September 11, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into SAB Biotherap

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into SAB Biotherap

NEW YORK, NY / ACCESSWIRE / September 12, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into SAB Biotherap

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into SAB Biotherapeu

NEW YORK, NY / ACCESSWIRE / September 10, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into SAB Biotherapeu

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into SAB Biotherapeutics, Inc

NEW YORK, NY / ACCESSWIRE / September 9, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into SAB Biotherapeutics, Inc

See News Rankings